Dr. Denise Figlewicz at the Subcommittee on Neurological Disease

I can think of two things. One is what Alex was referring to, which exists in the U.S. for the sort of nurturing of compounds from the lab to clinical trials. I've heard someone speak on this. There are actual pathways where you sort of shepherd a compound through. The amount of money involved in that is a million dollars--it's up there. But the same amount of money...